Related Experiment Videos
[Anhydrous theophylline in micropellets with prolonged action in asthmatic children]
Insights
Slow-release micro pellets theophylline effectively treated pediatric asthma symptoms. This secure medication demonstrated excellent tolerability in children aged 2-15 years.
Area of Science:
- Pediatric Pulmonology
- Pharmacology
- Clinical Therapeutics
Background:
- Asthma is a common chronic respiratory disease in children.
- Effective and safe long-term asthma management is crucial.
- Theophylline is a bronchodilator used in asthma treatment.
Purpose of the Study:
- To evaluate the efficacy, safety, and tolerability of slow-release micro pellets theophylline.
- To assess the treatment outcomes in pediatric asthma patients.
Main Methods:
- A study involving 168 children with asthma, aged 2 to 15 years.
- Administration of slow-release micro pellets theophylline.
- Monitoring of symptom improvement and patient tolerability.
Main Results:
- Symptom improvement was observed from the initiation of treatment.
- Excellent or good final evaluation was reported in 86.90% of cases.
- Excellent or good tolerability was reported in 94.64% of patients.
Conclusions:
- Slow-release micro pellets theophylline is highly effective for pediatric asthma.
- The drug demonstrated a favorable safety profile.
- Excellent tolerability supports its use in children with asthma.
Abstract:
The present study was realized to evaluate the effectiveness, security and tolerability of slow release micro pellets theophylline, in a group of 168 asthmatic children, between 2 and 15 years old. The improvement of the symptoms was obtained, since the treatment began. The final evaluation was considered excellent and good in 86.90% of the cases, and the tolerability, excellent and good in 94.64% of the patients. In conclusion the slow-release micro pellets theophylline is a very effective and secure drug, with a very good tolerability for the treatment of the asthmatics in pediatric age.